HRP20231020T1 - Postupak za proizvodnju n-(5-(4-(4-formil-3-fenil-1h-pirazol-1-il)pirimidin- 2-ilamino)-4-metoksi-2-morfolinofenil)akrilamida - Google Patents
Postupak za proizvodnju n-(5-(4-(4-formil-3-fenil-1h-pirazol-1-il)pirimidin- 2-ilamino)-4-metoksi-2-morfolinofenil)akrilamida Download PDFInfo
- Publication number
- HRP20231020T1 HRP20231020T1 HRP20231020TT HRP20231020T HRP20231020T1 HR P20231020 T1 HRP20231020 T1 HR P20231020T1 HR P20231020T T HRP20231020T T HR P20231020TT HR P20231020 T HRP20231020 T HR P20231020T HR P20231020 T1 HRP20231020 T1 HR P20231020T1
- Authority
- HR
- Croatia
- Prior art keywords
- methoxy
- tert
- carbamate
- butyl
- morpholinophenyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 14
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 9
- MZFYHCNLEGHDJF-UHFFFAOYSA-N C(C=C)(=O)NC=1C(=CC(=C(C=1)NC(OC(C)(C)C)=O)OC)N1CCOCC1 Chemical compound C(C=C)(=O)NC=1C(=CC(=C(C=1)NC(OC(C)(C)C)=O)OC)N1CCOCC1 MZFYHCNLEGHDJF-UHFFFAOYSA-N 0.000 claims 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 8
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 6
- MFNDJPOYVIUUBT-UHFFFAOYSA-N NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CCOCC1)OC Chemical compound NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CCOCC1)OC MFNDJPOYVIUUBT-UHFFFAOYSA-N 0.000 claims 5
- 239000003054 catalyst Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- GDUNRZJSTSLEPO-UHFFFAOYSA-N tert-butyl N-(2-methoxy-4-morpholin-4-yl-5-nitrophenyl)carbamate Chemical compound COC1=C(C=C(C(=C1)N1CCOCC1)[N+](=O)[O-])NC(OC(C)(C)C)=O GDUNRZJSTSLEPO-UHFFFAOYSA-N 0.000 claims 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 4
- KPUXYKMAEDAWET-UHFFFAOYSA-N C1=C(C(=CC(=C1OC)NC(=O)OC(C)(C)C)N(=O)=O)F Chemical compound C1=C(C(=CC(=C1OC)NC(=O)OC(C)(C)C)N(=O)=O)F KPUXYKMAEDAWET-UHFFFAOYSA-N 0.000 claims 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- XBMOTOKBPVZSBO-UHFFFAOYSA-N NC=1C(=CC(=C(C=1)NC(OC(C)(C)C)=O)OC)N1CCOCC1 Chemical compound NC=1C(=CC(=C(C=1)NC(OC(C)(C)C)=O)OC)N1CCOCC1 XBMOTOKBPVZSBO-UHFFFAOYSA-N 0.000 claims 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 4
- 235000019253 formic acid Nutrition 0.000 claims 4
- 229910052751 metal Inorganic materials 0.000 claims 4
- 239000002184 metal Substances 0.000 claims 4
- 229910052763 palladium Inorganic materials 0.000 claims 4
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 claims 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 3
- 150000007513 acids Chemical class 0.000 claims 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 3
- 229910052802 copper Inorganic materials 0.000 claims 3
- 239000010949 copper Substances 0.000 claims 3
- 229910017604 nitric acid Inorganic materials 0.000 claims 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 3
- 235000011181 potassium carbonates Nutrition 0.000 claims 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 3
- 235000011009 potassium phosphates Nutrition 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 3
- 239000012312 sodium hydride Substances 0.000 claims 3
- 229910000104 sodium hydride Inorganic materials 0.000 claims 3
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims 3
- 229910052725 zinc Inorganic materials 0.000 claims 3
- 239000011701 zinc Substances 0.000 claims 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 2
- 150000004703 alkoxides Chemical class 0.000 claims 2
- 229910052793 cadmium Inorganic materials 0.000 claims 2
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims 2
- 229940043279 diisopropylamine Drugs 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 229910052759 nickel Inorganic materials 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims 2
- 235000017550 sodium carbonate Nutrition 0.000 claims 2
- 239000001488 sodium phosphate Substances 0.000 claims 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
- 235000011008 sodium phosphates Nutrition 0.000 claims 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 claims 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims 1
- FYSIGSQCZXQTIH-UHFFFAOYSA-N 4-fluoro-2-methoxy-5-nitroaniline Chemical compound COC1=CC(F)=C([N+]([O-])=O)C=C1N FYSIGSQCZXQTIH-UHFFFAOYSA-N 0.000 claims 1
- OCCFXKQCKSLEII-UHFFFAOYSA-N 5-phenyl-1h-pyrazole-4-carbaldehyde Chemical compound C1=NNC(C=2C=CC=CC=2)=C1C=O OCCFXKQCKSLEII-UHFFFAOYSA-N 0.000 claims 1
- FDTRNFOBFZXXMG-UHFFFAOYSA-N C(=O)C=1C(=NN(C=1)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CCOCC1)OC)C1=CC=CC=C1 Chemical compound C(=O)C=1C(=NN(C=1)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CCOCC1)OC)C1=CC=CC=C1 FDTRNFOBFZXXMG-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 claims 1
- YAGCIXJCAUGCGI-UHFFFAOYSA-N butoxycarbonyl butyl carbonate Chemical compound CCCCOC(=O)OC(=O)OCCCC YAGCIXJCAUGCGI-UHFFFAOYSA-N 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims 1
- 229910052808 lithium carbonate Inorganic materials 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical group [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims 1
- JKDRQYIYVJVOPF-FDGPNNRMSA-L palladium(ii) acetylacetonate Chemical compound [Pd+2].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O JKDRQYIYVJVOPF-FDGPNNRMSA-L 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 239000011736 potassium bicarbonate Substances 0.000 claims 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims 1
- 235000015497 potassium bicarbonate Nutrition 0.000 claims 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (15)
1. Postupak za proizvodnju N-(5-(4-(4-formil-3-fenil-1H-pirazol-1-il)pirimidin-2-ilamino)-4-metoksi-2-morfolinofenil)akrilamida, naznačen time, da postupak obuhvaća reakciju terc-butil (5-akrilamido-2-metoksi-4-morfolinofenil)karbamata ili N-(5-amino-4-metoksi-2-morfolinofenil)akrilamida sa spojem Formule 13:
[image]
u kojoj Z je halogen.
2. Postupak prema patentnom zahtjevu 1, naznačen time, da se N-(5-amino-4-metoksi-2-morfolinofenil)akrilamid dobiva putem reakcije terc-butil (5-akrilamido-2-metoksi-4-morfolinofenil)karbamata s kiselinom.
3. Postupak prema patentnom zahtjevu 2, naznačen time, da se radi o jednoj ili više kiselina odabranih iz skupine koju čine klorovodična kiselina, sumporna kiselina, fosforna kiselina, dušična kiselina, octena kiselina, mravlja kiselina, sulfonska kiselina i p-toluensulfonska kiselina.
4. Postupak prema patentnom zahtjevu 1, naznačen time, da se reakcija terc-butil (5-akrilamido-2-metoksi-4-morfolinofenil)karbamata sa spojem Formule 13, provodi u prisutnosti kiseline.
5. Postupak prema patentnom zahtjevu 4, naznačen time, da se radi o jednoj ili više kiselina odabranih iz skupine koju čine klorovodična kiselina, sumporna kiselina, fosforna kiselina, dušična kiselina, octena kiselina, mravlja kiselina, sulfonska kiselina i p-toluensulfonska kiselina.
6. Postupak prema patentnom zahtjevu 1, naznačen time, da se reakcija N-(5-amino-4-metoksi-2-morfolinofenil)akrilamida sa spojem Formule 13, provodi u prisutnosti metalnog katalizatora, liganda, i baze,
opcionalno:
(i) pri čemu se radi o jednom ili više metalnih katalizatora odabranih iz skupine koju čine paladij, bakar, željezo, kadmij, cink, i nikal; ili
(ii) pri čemu se radi o jednom ili više metalnih katalizatora odabranih iz skupine koju čine paladij, bakar, željezo, kadmij, cink, i nikal, i pri čemu metalni katalizator je paladij acetat, paladij acetilacetonat, bis(dibenzilidenacetonat)paladij, ili tris(dibenzilidenacetonat)dipaladij; ili
(iii) pri čemu se radi o jednom ili više liganda odabranih iz skupine koju čine 2,2'-bis(difenilfosfino)-1,1'-binaftalen, 1,1'-bis(defenilfosfino)ferocen, i 4,5-bis(difenilfosfino)-9,9-dimetilksanten; ili
(iv) pri čemu se radi o jednoj ili više baza odabranih iz skupine koju čine kalijev terc-butoksid, natrijev hidroksid, kalijev hidroksid, natrijev hidrid, natrijev karbonat, kalijev karbonat, kalijev fosfat, natrijev fosfat, cezijev karbonat, 1,8-diazabiciklo[5.4.0]undek-7-en, 1,4-diazabiciklo[2.2.2]oktan, 1,5-diazabiciklo[4.3.0]non-5-en, piridin, trietilamin, diizopropilamin, i diizopropiletilamin.
7. Postupak prema patentnom zahtjevu 1, naznačen time, da se reakcija N-(5-amino-4-metoksi-2-morfolinofenil)akrilamida sa spojem Formule 13, provodi u prisutnosti kiseline,
opcionalno gdje se radi o jednoj ili više kiselina odabranih iz skupine koju čine klorovodična kiselina, sumporna kiselina, fosforna kiselina, dušična kiselina, octena kiselina, mravlja kiselina, sulfonska kiselina i p-toluensulfonska kiselina.
8. Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da se terc-butil (5-akrilamido-2-metoksi-4-morfolinofenil)karbamat dobiva putem postupka koji obuhvaća:
(i) reakciju terc-butil (5-amino-2-metoksi-4-morfolinofenil)karbamata sa spojem Formule 11 u svrhu tvorbe spoja Formule 5; i
(ii) reakciju spoja Formule 5 s bazom u svrhu dobivanja terc-butil (5-akrilamido-2-metoksi-4-morfolinofenil)karbamata:
[image]
[image]
gdje su X i Y neovisno jedan od drugoga, halogeni.
9. Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da se terc-butil (5-akrilamido-2-metoksi-4-morfolinofenil)karbamat dobiva putem postupka koji obuhvaća:
(i) reakciju terc-butil (5-amino-2-metoksi-4-morfolinofenil)karbamata sa spojem Formule 11 u svrhu tvorbe spoja Formule 5; i
(ii) reakciju spoja Formule 5 s bazom u svrhu dobivanja terc-butil (5-akrilamido-2-metoksi-4-morfolinofenil)karbamata:
[image]
[image]
[image]
gdje su X i Y neovisno jedan od drugoga, halogeni, i:
a) gdje se Korak (i) i Korak (ii) provode putem reakcije u jednom reaktoru bez izoliranja spoja Formule 5; ili
b) gdje se reakcija iz Koraka (i) ili reakcija iz Koraka (ii) provodi u prisutnosti jedne ili više baza odabranih iz skupine koju čine kalijev terc-butoksid, natrijev hidroksid, kalijev hidroksid, litijev hidroksid, natrijev hidrid, natrijev karbonat, natrijev bikarbonat, kalijev karbonat, kalijev fosfat, natrijev fosfat, 1,8-diazabiciklo[5.4.0]undek-7-en, 1,4-diazabiciklo[2.2.2]oktan, 1,5-diazabiciklo[4.3.0]non-5-en, piridin, trietilamin, diizopropilamin, i diizopropiletilamin; ili
c) gdje se terc-butil (5-amino-2-metoksi-4-morfolinofenil)karbamat dobiva putem izvođenja redukcije terc-butil (2-metoksi-4-morfolino-5-nitrofenil)karbamata, opcionalno:
(i) pri čemu se redukcija izvodi s redukcijskim agensom odabranim iz skupine koju čine mravlja kiselina i amonijev format; ili
(ii) pri čemu se redukcija izvodi u prisutnosti katalizatora odabranog iz skupine koju čine paladij, paladij/ugljik, cink, bakar, magnezij, i platina; ili
(iii) pri čemu se terc-butil (2-metoksi-4-morfolino-5-nitrofenil)karbamat dobiva putem reakcije terc-butil (4-fluoro-2-metoksi-5-nitrofenil)karbamata s morfolinom; ili
(iv) pri čemu se terc-butil (2-metoksi-4-morfolino-5-nitrofenil)karbamat dobiva putem reakcije terc-butil (4-fluoro-2-metoksi-5-nitrofenil)karbamata s morfolinom, i pri čemu se reakcija provodi u prisutnosti jedne ili više baza odabranih iz skupine koju čine natrijev hidrid, natrijev C1 ~ C6 alkoksid, kalijev C1 ~ C6 alkoksid, natrijev karbonat, kalijev karbonat, litijev karbonat, cezijev karbonat, natrijev bikarbonat, kalijev bikarbonat, kalijev fosfat, 1,8-diazabiciklo[5.4.0]undek-7-en, 1,4-diazabiciklo[2.2.2]oktan, 1,5-diazabiciklo[4.3.0]non-5-en, piridin, dimetilaminopiridin, trietilamin, i diizopropiletilamin; ili
(v) pri čemu se terc-butil (2-metoksi-4-morfolino-5-nitrofenil)karbamat dobiva putem reakcije terc-butil (4-fluoro-2-metoksi-5-nitrofenil)karbamata s morfolinom, i pri čemu se terc-butil (4-fluoro-2-metoksi-5-nitrofenil)karbamat dobiva putem reakcije 4-fluoro-2-metoksi-5-nitroanilin s dibutil dikarbonatom.
10. Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da se spoj Formule 13 dobiva putem reakcije spoja Formule 14 s 3-fenil-1H-pirazol-4-karbaldehidom:
[image]
gdje su Z i Z' neovisno jedan od drugoga, halogeni.
11. Spoj, naznačen time, da je N-(5-amino-4-metoksi-2-morfolinofenil)akrilamid.
12. Spoj, naznačen time, da je terc-butil (5-akrilamido-2-metoksi-4-morfolinofenil)karbamat.
13. Spoj Formule 5 ili njegova sol, naznačen time, da je:
[image]
gdje Y je halogen.
14. Spoj, naznačen time, da je terc-butil (5-amino-2-metoksi-4-morfolinofenil)karbamat.
15. Spoj, naznačen time, da je terc-butil (2-metoksi-4-morfolino-5-nitrofenil)karbamat.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170096226 | 2017-07-28 | ||
| PCT/KR2018/008383 WO2019022487A1 (en) | 2017-07-28 | 2018-07-25 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF A SELECTIVE INHIBITOR TO PROTEIN KINASE AND METHODS FOR THEIR PREPARATION |
| EP18838718.7A EP3658547B1 (en) | 2017-07-28 | 2018-07-25 | Process for preparing n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231020T1 true HRP20231020T1 (hr) | 2023-12-08 |
Family
ID=65040643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231020TT HRP20231020T1 (hr) | 2017-07-28 | 2018-07-25 | Postupak za proizvodnju n-(5-(4-(4-formil-3-fenil-1h-pirazol-1-il)pirimidin- 2-ilamino)-4-metoksi-2-morfolinofenil)akrilamida |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11198684B2 (hr) |
| EP (1) | EP3658547B1 (hr) |
| JP (1) | JP7189932B2 (hr) |
| KR (1) | KR20230137282A (hr) |
| CN (1) | CN111295381A (hr) |
| AU (1) | AU2018308164B2 (hr) |
| BR (1) | BR112020001457A2 (hr) |
| CA (1) | CA3070070A1 (hr) |
| CO (1) | CO2020000371A2 (hr) |
| DK (1) | DK3658547T3 (hr) |
| EA (1) | EA038078B1 (hr) |
| ES (1) | ES2959967T3 (hr) |
| FI (1) | FI3658547T3 (hr) |
| HR (1) | HRP20231020T1 (hr) |
| HU (1) | HUE063043T2 (hr) |
| IL (1) | IL271975B (hr) |
| LT (1) | LT3658547T (hr) |
| MA (1) | MA49705A (hr) |
| NZ (1) | NZ761158A (hr) |
| PH (1) | PH12020500093A1 (hr) |
| PL (1) | PL3658547T3 (hr) |
| PT (1) | PT3658547T (hr) |
| RS (1) | RS64545B1 (hr) |
| SA (1) | SA520411115B1 (hr) |
| SG (1) | SG11201913556SA (hr) |
| SI (1) | SI3658547T1 (hr) |
| UA (1) | UA125595C2 (hr) |
| WO (1) | WO2019022487A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3658553T (pt) * | 2017-07-28 | 2022-09-23 | Yuhan Corp | Intermediários úteis para a síntese de derivados de aminopirimidina, processo para preparar os mesmos, e processo para preparar derivados de aminopirimidina usando os mesmos |
| EA202090383A1 (ru) | 2017-07-28 | 2020-06-15 | Юхан Корпорейшн | Усовершенствованный способ получения производных аминопиримидина |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| WO2020230091A1 (en) | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3549934A1 (en) | 2008-06-27 | 2019-10-09 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| US8629132B2 (en) | 2009-11-13 | 2014-01-14 | Genosco | Kinase inhibitors |
| JP5427321B2 (ja) * | 2011-07-27 | 2014-02-26 | アストラゼネカ アクチボラグ | ２−（２，４，５−置換−アニリノ）ピリミジン化合物 |
| WO2013096637A1 (en) * | 2011-12-23 | 2013-06-27 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| CN104203943B (zh) * | 2012-01-20 | 2017-12-29 | 盖诺斯克公司 | 取代的嘧啶化合物及其作为syk抑制剂的用途 |
| EP3144292B1 (en) * | 2014-04-14 | 2020-08-26 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd | 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof |
| CN105461695B (zh) * | 2014-09-29 | 2018-03-27 | 齐鲁制药有限公司 | 嘧啶或三嗪衍生物及其制备方法和用途 |
| CN105524068B (zh) * | 2014-09-30 | 2017-11-24 | 上海海雁医药科技有限公司 | 氮杂双环衍生物、其制法与医药上的用途 |
| KR102208775B1 (ko) * | 2014-10-13 | 2021-01-28 | 주식회사유한양행 | Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물 |
| CN104788427B (zh) * | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
| JP2019501222A (ja) * | 2016-01-07 | 2019-01-17 | シーエス ファーマテック リミテッド | Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬 |
| CN106083736A (zh) * | 2016-06-21 | 2016-11-09 | 郑州泰基鸿诺医药股份有限公司 | 一种嘧啶类化合物、egfr抑制剂及其应用 |
-
2018
- 2018-07-25 NZ NZ761158A patent/NZ761158A/en not_active IP Right Cessation
- 2018-07-25 UA UAA202001302A patent/UA125595C2/uk unknown
- 2018-07-25 US US16/633,756 patent/US11198684B2/en active Active
- 2018-07-25 WO PCT/KR2018/008383 patent/WO2019022487A1/en active Application Filing
- 2018-07-25 JP JP2020504208A patent/JP7189932B2/ja active Active
- 2018-07-25 ES ES18838718T patent/ES2959967T3/es active Active
- 2018-07-25 EP EP18838718.7A patent/EP3658547B1/en active Active
- 2018-07-25 CN CN201880048980.9A patent/CN111295381A/zh active Pending
- 2018-07-25 EA EA202090384A patent/EA038078B1/ru unknown
- 2018-07-25 HR HRP20231020TT patent/HRP20231020T1/hr unknown
- 2018-07-25 FI FIEP18838718.7T patent/FI3658547T3/fi active
- 2018-07-25 LT LTEPPCT/KR2018/008383T patent/LT3658547T/lt unknown
- 2018-07-25 IL IL271975A patent/IL271975B/en unknown
- 2018-07-25 BR BR112020001457-5A patent/BR112020001457A2/pt unknown
- 2018-07-25 AU AU2018308164A patent/AU2018308164B2/en active Active
- 2018-07-25 HU HUE18838718A patent/HUE063043T2/hu unknown
- 2018-07-25 CA CA3070070A patent/CA3070070A1/en active Pending
- 2018-07-25 SG SG11201913556SA patent/SG11201913556SA/en unknown
- 2018-07-25 RS RS20230685A patent/RS64545B1/sr unknown
- 2018-07-25 MA MA049705A patent/MA49705A/fr unknown
- 2018-07-25 SI SI201830982T patent/SI3658547T1/sl unknown
- 2018-07-25 DK DK18838718.7T patent/DK3658547T3/da active
- 2018-07-25 PT PT188387187T patent/PT3658547T/pt unknown
- 2018-07-25 PL PL18838718.7T patent/PL3658547T3/pl unknown
-
2020
- 2020-01-14 PH PH12020500093A patent/PH12020500093A1/en unknown
- 2020-01-15 CO CONC2020/0000371A patent/CO2020000371A2/es unknown
- 2020-01-22 SA SA520411115A patent/SA520411115B1/ar unknown
-
2023
- 2023-09-21 KR KR1020230126377A patent/KR20230137282A/ko not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231020T1 (hr) | Postupak za proizvodnju n-(5-(4-(4-formil-3-fenil-1h-pirazol-1-il)pirimidin- 2-ilamino)-4-metoksi-2-morfolinofenil)akrilamida | |
| WO2018064050A3 (en) | Methods of preparing a catalyst | |
| HRP20220017T1 (hr) | Postupci pripreme novih inhibitora idh1 | |
| EA201070139A1 (ru) | Способ карбонилирования этиленненасыщенных соединений и каталитическая система | |
| HRP20221444T1 (hr) | Postupci za pripravu pi3k inhibitora | |
| NZ730843A (en) | Synthesis of copanlisib and its dihydrochloride salt | |
| HRP20180948T1 (hr) | Postupak za proizvodnju aminokiselinskih spojeva | |
| CN104610088B (zh) | 一种利用co2合成n,n-二烷基草酰胺的方法 | |
| CN102675163B (zh) | 一种磺酰胺的制备方法 | |
| Hirai et al. | C–N and C–S Bond Forming Cross Coupling in Water with Amphiphilic Resin-supported Palladium Complexes | |
| Muzart | On the behavior of amines in the presence of Pd0 and PdII species | |
| CN105198821A (zh) | 洛昔替尼的制备方法 | |
| RU2016141426A (ru) | Способ получения 3-(3-(4-(1-аминоциклобутил)фенил)-5-фенил-3h-имидазо[4,5-b]пиридин-2-ил)пиридин-2-амина | |
| CN103130654A (zh) | 3,3’-二甲基-4,4’-二氨基二苯甲烷（mdt）的制备方法 | |
| CN103172639B (zh) | 一种基于盐酸胍的六元二环胍的制备方法 | |
| MX2010008663A (es) | Procedimiento para preparar bifenilanilidas sustituidas. | |
| JP6336579B2 (ja) | ピリジン又はピラジン含有化合物 | |
| Nair et al. | Nickel-catalysed fluoromethylation reactions | |
| CN105693696A (zh) | 一种氨基吡唑基双吡啶及其制备方法 | |
| JPWO2015098717A1 (ja) | ニトロ化合物の製造方法 | |
| SK31398A3 (en) | Method for producing 2,6-pyridinedicarboxylic acids esters | |
| JP2004277409A (ja) | ハロゲン化芳香族アミンの製造法 | |
| RU2012116047A (ru) | Способ и катализатор | |
| JP6216609B2 (ja) | 担持触媒製造用組成物の製造方法 | |
| CN104311474B (zh) | 一种3‑炔基吡啶类化合物的合成方法 |